openPR Logo
Press release

Neurological Biomarkers Market to Build Excessive Revenue by Crossing $8,579.9 Million by 2025: Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, Athena Diagnostics and More

02-21-2019 10:16 AM CET | Health & Medicine

Press release from: Allied Market Research

Neurological Biomarkers Market

Neurological Biomarkers Market

The Neurological Biomarkers Market for Alzheimer’s and Parkinson’s disease was valued at $3,958.5 million in 2017, and is expected to reach $8,579.9 million by 2025, registering a CAGR of 10.1% from 2018-2025.

Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are characterized by gradual loss of cognitive function, dementia, and problems with movements.

The report provides a comprehensive analysis of the key players operating in the neurological biomarkers market for Alzheimer’s and Parkinson’s disease such as Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, Athena Diagnostics, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, Psynova Neurotech, and Bio-Rad Laboratories.

Get Sample PDF Brochure of Neurological Biomarkers Market Study at: https://www.alliedmarketresearch.com/request-sample/3555

Currently, research activities focused on biomarkers in the field of neurodegenerative diseases is significantly important, owing to surge in incidence of Alzheimer’s and Parkinson’s diseases worldwide.

The key factors that boost the growth of the neurological biomarkers market for Alzheimer’s and Parkinson’s diseases include increase in focus on developing cost-effective biomarker testing and rise in demand for noninvasive diagnostic techniques for Alzheimer’s and Parkinson’s.

In addition, surge in adoption of neurological biomarkers in clinical trials supplement the market growth. However, implementation of stringent government regulations towards the approval of commercial use of biomarkers and emerging ethical issues regarding early diagnosis of Alzheimer’s and Parkinson’s diseases are expected to hamper the market growth. Conversely, rise in demand for personalized medicine is anticipated to offer profitable opportunities for the expansion of the market.

Neurodegenerative biomarkers for Alzheimer’s disease based on region is categorized into U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of world (ROW). U.S. was the leading market in 2017, followed by Europe.

The dominance of U.S. in the Alzheimer’s market is attributed to rise in patient population that suffers from this disease. For instance, Alzheimer’s disease (AD) affects five million Americans per year, and is the sixth leading cause of death in the U.S. However, Asia-Pacific is projected to emerge as a lucrative market in the future, due to the presence of large patient pool affected by Alzheimer's disease and surge in geriatric population. Moreover, increase in awareness towards Alzheimer's disease is projected to augment the growth of the market in ROW.

Do Purchase Enquiry at : https://www.alliedmarketresearch.com/purchase-enquiry/3555

Neurodegenerative biomarkers for Alzheimer’s disease based on region is categorized into U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of world (ROW). U.S. was the leading market in 2017, and is expected to continue this trend throughout the forecast period.

This is attributed to rise in expenditure on the management of Parkinson’s disease in the country. As of 2017, U.S. had a population of 326,506,644 individuals, and about 60,000 individuals are diagnosed with Parkinson’s diseases every year. Thus, significant prevalence of this disease among the U.S. population drives the growth of the market. However, China is projected to emerge as a lucrative market in future, due to the higher prevalence of Parkinson’s disease observed in males in 2017.

Key Benefits for Stakeholders

• The study provides an in-depth analysis with the current trends and future estimations of the neurological biomarkers market for Alzheimer’s and Parkinson’s diseases.
• Comprehensive analysis of the factors that drive and restrict the market growth is provided.
• The quantitative analysis of the industry from 2017 to 2025 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of key regions is provided to understand the neurological biomarkers market for Alzheimer’s and Parkinson’s diseases.
• Key players and their strategies are analyzed to understand the competitive outlook of the market.

About us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David C
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neurological Biomarkers Market to Build Excessive Revenue by Crossing $8,579.9 Million by 2025: Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, Athena Diagnostics and More here

News-ID: 1606206 • Views:

More Releases from Allied Market Research

Sustainable Home Décor Market Growing at 5.5% CAGR to Hit USD 556.3 billion by 2031 | Growth, Share Analysis, Company Profiles
Sustainable Home Décor Market Growing at 5.5% CAGR to Hit USD 556.3 billion by …
The global Sustainable Home Decor Market Size was valued at $331.0 billion in 2021, and is projected to reach $556.3 billion by 2031, growing at a CAGR of 5.5% from 2022 to 2031. A complete and wide-ranging evaluation of the aspects that drive and restrain market growth is also provided throughout the study. This detailed exploration of the market size and its proper segmentation help the market players define the
Tomato Puree Market Rapidly Growing Dynamics with Industry Analysis 2032
Tomato Puree Market Rapidly Growing Dynamics with Industry Analysis 2032
The global tomato puree industry was valued at $5,189.9 million in 2022, and is projected to reach $7,699.5 million by 2032, registering with a CAGR of 4.1% from 2023 to 2032. Tomato puree plays a major role in the daily culinary routines of individuals, making significant contributions to the global food and beverage industry. The growing awareness of diverse and authentic flavors, along with a rising interest in international cuisines, has
Emerging Technologies in Structural Steel Tube Market in Glob: Innovations and Future Prospects by 2033
Emerging Technologies in Structural Steel Tube Market in Glob: Innovations and F …
According to the report, "the structural steel tube market" was valued at $105.3 billion in 2023, and is estimated to reach $167.5 billion by 2033, growing at a CAGR of 4.8% from 2024 to 2033. Allied Market Research published a report, titled, "Structural Steel Tube Market By Type (Hot-Rolled Steel and Cold-Rolled Steel), Material (Stainless Steel Tube, Carbon Steel Tube, Alloy Steel Tube, and Others), Sales Type (Direct,
Costume Jewelry Market Size Worth USD 86.8 billion by 2033 | Growth Rate (CAGR) of 6.8%
Costume Jewelry Market Size Worth USD 86.8 billion by 2033 | Growth Rate (CAGR) …
According to a new report published by Allied Market Research, titled, "costume jewelry market" was valued at $45.2 billion in 2023, and is projected to reach $86.8 billion by 2033, growing at a CAGR of 6.8% from 2024 to 2033. Get Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/2093 Costume jewelry refers to decorative pieces made of inexpensive materials such as base metals, glass, plastic, or synthetic stones, often adorned with

All 5 Releases


More Releases for Alzheimer

Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928 Key Takeaways • Disease-modifying
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,